375 related articles for article (PubMed ID: 31822380)
1. TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.
Chapman L; Ledet EM; Barata PC; Cotogno P; Manogue C; Moses M; Christensen BR; Steinwald P; Ranasinghe L; Layton JL; Lewis BE; Sartor O
Clin Genitourin Cancer; 2020 Apr; 18(2):148-154. PubMed ID: 31822380
[TBL] [Abstract][Full Text] [Related]
2. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer.
Moses M; Niu A; Lilly MB; Hahn AW; Nussenzveig R; Ledet E; Manogue C; Cotogno P; Lewis B; Layton J; Agarwal N; Sartor O; Barata PC
Cancer Treat Res Commun; 2020; 24():100193. PubMed ID: 32702615
[TBL] [Abstract][Full Text] [Related]
3.
De Laere B; Oeyen S; Mayrhofer M; Whitington T; van Dam PJ; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert EG; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff IE; van Dam V; Brouwer A; Goossens D; Heyrman L; Van den Eynden GG; Rutten A; Del Favero J; Rantalainen M; Rajan P; Sleijfer S; Ullén A; Yachnin J; Grönberg H; Van Laere SJ; Lindberg J; Dirix LY
Clin Cancer Res; 2019 Mar; 25(6):1766-1773. PubMed ID: 30209161
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
Conteduca V; Wetterskog D; Sharabiani MTA; Grande E; Fernandez-Perez MP; Jayaram A; Salvi S; Castellano D; Romanel A; Lolli C; Casadio V; Gurioli G; Amadori D; Font A; Vazquez-Estevez S; González Del Alba A; Mellado B; Fernandez-Calvo O; Méndez-Vidal MJ; Climent MA; Duran I; Gallardo E; Rodriguez A; Santander C; Sáez MI; Puente J; Gasi Tandefelt D; Wingate A; Dearnaley D; ; ; Demichelis F; De Giorgi U; Gonzalez-Billalabeitia E; Attard G
Ann Oncol; 2017 Jul; 28(7):1508-1516. PubMed ID: 28472366
[TBL] [Abstract][Full Text] [Related]
5. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.
Belic J; Graf R; Bauernhofer T; Cherkas Y; Ulz P; Waldispuehl-Geigl J; Perakis S; Gormley M; Patel J; Li W; Geigl JB; Smirnov D; Heitzer E; Gross M; Speicher MR
Int J Cancer; 2018 Sep; 143(5):1236-1248. PubMed ID: 29574703
[TBL] [Abstract][Full Text] [Related]
6. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES
Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer.
Gupta S; Halabi S; Kemeny G; Anand M; Giannakakou P; Nanus DM; George DJ; Gregory SG; Armstrong AJ
Mol Cancer Res; 2021 Jun; 19(6):1040-1050. PubMed ID: 33771885
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.
Sonpavde G; Agarwal N; Pond GR; Nagy RJ; Nussenzveig RH; Hahn AW; Sartor O; Gourdin TS; Nandagopal L; Ledet EM; Naik G; Armstrong AJ; Wang J; Bilen MA; Gupta S; Grivas P; Pal SK; Lanman RB; Talasaz A; Lilly MB
Cancer; 2019 May; 125(9):1459-1469. PubMed ID: 30620391
[TBL] [Abstract][Full Text] [Related]
9. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
10. Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.
De Laere B; Rajan P; Grönberg H; Dirix L; Lindberg J;
JAMA Oncol; 2019 Jul; 5(7):1060-1062. PubMed ID: 31046065
[TBL] [Abstract][Full Text] [Related]
11. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
Annala M; Struss WJ; Warner EW; Beja K; Vandekerkhove G; Wong A; Khalaf D; Seppälä IL; So A; Lo G; Aggarwal R; Small EJ; Nykter M; Gleave ME; Chi KN; Wyatt AW
Eur Urol; 2017 Jul; 72(1):34-42. PubMed ID: 28259476
[TBL] [Abstract][Full Text] [Related]
12. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
13. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Lolli C; De Lisi D; Conteduca V; Gurioli G; Scarpi E; Schepisi G; Ravaglia G; Menna C; Farolfi A; Altavilla A; Burgio SL; Tonini G; Santini D; De Giorgi U
Prostate; 2019 Aug; 79(11):1211-1220. PubMed ID: 31251826
[TBL] [Abstract][Full Text] [Related]
14. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
Chen WS; Aggarwal R; Zhang L; Zhao SG; Thomas GV; Beer TM; Quigley DA; Foye A; Playdle D; Huang J; Lloyd P; Lu E; Sun D; Guan X; Rettig M; Gleave M; Evans CP; Youngren J; True L; Lara P; Kothari V; Xia Z; Chi KN; Reiter RE; Maher CA; Feng FY; Small EJ; Alumkal JJ;
Eur Urol; 2019 Nov; 76(5):562-571. PubMed ID: 30928160
[TBL] [Abstract][Full Text] [Related]
15. p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer.
Maughan BL; Guedes LB; Boucher K; Rajoria G; Liu Z; Klimek S; Zoino R; Antonarakis ES; Lotan TL
Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):260-268. PubMed ID: 29302046
[TBL] [Abstract][Full Text] [Related]
16. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
[TBL] [Abstract][Full Text] [Related]
17. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
Attard G; Antonarakis ES
Nat Rev Urol; 2016 Dec; 13(12):697-698. PubMed ID: 27804988
[No Abstract] [Full Text] [Related]
19. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN
JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695
[TBL] [Abstract][Full Text] [Related]
20. Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.
Gupta S; Li J; Kemeny G; Bitting RL; Beaver J; Somarelli JA; Ware KE; Gregory S; Armstrong AJ
Clin Cancer Res; 2017 Mar; 23(5):1346-1357. PubMed ID: 27601596
[No Abstract] [Full Text] [Related]
[Next] [New Search]
